Table 2.
Demographics, cognitive scores, Alzheimer’s disease biomarker and risk characteristics for the three flortaucipir progression groups in ADNI, AVID-05, and HABS cohorts. Baseline refers to first flortaucipir PET observation time point.
| Stable (N=440) |
Moderate accumulator (N=96) |
Fast accumulator (N=38) |
Stable vs Moderate accumulator |
Stable vs Fast accumulator |
Moderate accumulator vs Fast accumulator |
Uncertain classification* (N=39) |
|
|---|---|---|---|---|---|---|---|
| Variables | Mean (SD) | Mean (SD) | Mean (SD) | Pr | Pr | Pr | Mean (SD) |
| Age (years; baseline) | 73.1 (7.7) | 76.1 (7.3) | 70.6 (9.8) | <0.001 | 0.05 | <0.001 | 76.7 (8.0) |
| Education | 16.2 (2.8) | 16.3 (2.3) | 15.1 (2.3) | 0.55 | 0.02 | 0.005 | 16.0 (2.5) |
| MMSE (baseline) | 28.7 (1.8) | 26.5 (3.3) | 23.0 (4.2) | <0.001 | <0.001 | <0.001 | 26.8 (2.6) |
| ΔMMSE## | −0.04 (0.33) | −0.6 (0.7) | −1.7 (0.9) | <0.001 | <0.001 | <0.001 | −0.57 (0.55) |
| CDR-SB# (baseline) | 0.46 (1.1) | 1.5 (1.6) | 4.4 (3.0) | <0.001 | <0.001 | <0.001 | 1.7 (2.0) |
| ΔCDR-SB## | 0.09 (0.3) | 0.5 (0.6) | 1.5 (0.8) | <0.001 | <0.001 | <0.001 | 0.45 (0.46) |
| ADAS-Cog# (baseline) | 9.3 (4.2) | 13.6 (6.2) | 21.4 (6.9) | <0.001 | <0.001 | <0.001 | 14.2 (5.2) |
| ΔADAS-Cog## | 1.1 (0.4) | 1.6 (0.6) | 2.7 (0.7) | <0.001 | <0.001 | <0.001 | 1.6 (0.50) |
| GDS# (baseline) | 1.9 (2.6) | 2.1 (2.1) | 1.8 (1.8) | 0.59 | 0.83 | 0.56 | 1.8 (2.3) |
| ΔGDS## | 0.06 (0.15) | 0.12 (0.14) | 0.10 (0.17) | 0.04 | 0.37 | 0.72 | 0.084 (0.16) |
| WML ## burden (cc; baseline) | 1.2 (8.0) | 5.8 (17.8) | 3.8 (8.2) | 0.01 | 0.09 | 0.91 | 3.07 (10.7) |
| Meta ROI thickness (mm; baseline) | 3.0 (0.32) | 2.6 (0.40) | 2.5 (0.45) | <0.001 | <0.001 | 0.29 | 2.7 (0.40) |
| Duration of flortaucipir PET follow-up (years) | 2.2 (1.1) | 1.7 (0.8) | 1.5 (0.5) | <0.001 | <0.001 | 0.17 | 1.7 (0.9) |
| % Female (N) | 50% (218) | 55% (53) | 55% (21) | 0.37 | 0.61 | 1 | 36% (14) |
| % Black or African American# (N) | 7.7% (26/338) | 6.2% (4/64) | 0% (0/18) | 18% (5/27) | |||
| % Asian# (N) | 0.6% (2/338) | 0% (0/64) | 0% (0/18) | 7% (2/27) | |||
| % Hispanic or Latinx# (N) | 3.5% (12/339) | 4.7% (3/64) | 5.6% (1/18) | 0.72 | 0.50 | 1.0 | 26% (7/27) |
| % APOE ε4 carriers (N) | 30% (131) | 63% (61) | 71% (27) | <0.001 | 0.002 | 0.88 | 63% (22/35) |
| % Aβ(N) (first observation) | 32% (141) | 88% (84) | 97% (37) | <0.001 | <0.001 | 0.18 | 69% (27) |
| % CU (N) (first observation) | 70% (308) | 29% (28) | 0% (0) | <0.001 | <0.001 | <0.001 | 31% (12) |
| % MCI (N) (first observation) | 25% (111) | 47% (45) | 37% (14) | 46% (18) | |||
| % Dementia (N) (first observation) | 5% (21) | 24% (23) | 63% (24) | 23% (9) | |||
| % w/ 2-timepoint flortaucipir PET scans (N) | 54% (240) | 52% (50) | 39% (15) | 0.73 | 0.09 | 0.25 | 49% (19) |
| % w/ 3-timepoint flortaucipir PET scans (N) | 46% (200) | 48% (46) | 61% (23) | 51% (20) | |||
| % ADNI cases (N) | 52% (228) | 60% (58) | 47% (18) | <0.001 | <0.001 | 0.04 | 56% (22) |
| % AVID-05 cases (N) | 22% (98) | 32% (31) | 53% (20) | 31% (5) | |||
| % HABS cases (N) | 26% (114) | 7% (7) | 0% (0) | 23% (5) |
APOE: apolipoprotein E gene; cc: cubic centimeter; CDR-SB: Clinical Dementia Rating – Sum of Boxes; GDS: Geriatric Depression Score; MMSE: Mini-Mental State Examination; PET: positron emission tomography
#
Data only available for ADNI and HABS participants.
##
Data only available for ADNI participants.
*
Uncertain classification based on highest posterior density credible intervals; 46% (18/39) were classified as stable, 41% (16/39) as moderate progressor, and 13% (5/39) as fast progressor